Skip to main content
SpringerLink
Log in

Recombinant methionyl granulocyte colony-stimulating factor (filgrastim): A new dimension in immunotherapy

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Avalos BR, Gasson JC et al. (1989) Molecular characterization of the human G-CSF receptor. J Cell Biochem 13 [part C, Suppl 0]:22

    Google Scholar 

  2. Avalos BR, Gasson JC et al. (1990) Human granulocyte colony-stimulating factor: biologic activities and receptor characterization on hematopoietic cells and small cell lung cancer cell lines. Blood 75:851–857

    Google Scholar 

  3. Begley CD, Metcalf D et al. (1988) Binding characteristics and proliferative action of purified granulocyte colony-stimulating factor (G-CSF) on normal and leukemic human promyelocytes. Exp Hematol 16:71–79

    Google Scholar 

  4. Bodey GP Buckley M et al. (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340

    Google Scholar 

  5. Bonilla M, Gillio AP et al. (1989) Effects of recombinant human granulocyte colony-stimulating factor on neutropenia of patients with congenital agranulocytosis. N Engl J Med 320:1574–1580

    Google Scholar 

  6. Bosly A, Coiffier B et al. (1992) Bone marrow transplantation prolongs survival after relapse in aggressive lymphoma patients treated with the LNH-84 regimen. J Clin Oncol 10:1615–1623

    Google Scholar 

  7. Bronchud M (1993) Can hematopoietic growth factors be used to improve the success of cytotoxic chemotherapy? Anticancer Drugs 4:127–139

    Google Scholar 

  8. Bronchud MH, Potter MR et al. (1988) In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. Br J Cancer 58:64–69

    Google Scholar 

  9. Bronchud MH, Scarffe JH et al. (1987) Phase-I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 56:809–813

    Google Scholar 

  10. Brugger W, Birken R et al. (1993) Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte colony-stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin. Br J Haematol 84:402–407

    Google Scholar 

  11. Brugger W, Möcklin W et al. (1993) Ex vivo expansion of enriched peripheral blood CD34 + progenitor cells by stem cell factor, interleukin 1b (IL-1Β), IL-6, IL-3, interferon-γ, and erythropoietin. Blood 81:2579–2584

    Google Scholar 

  12. Budman DR, Wood W et al. (1992) Initial findings of CALGB 8541: a dose and dose-intensity trial of cyclophosphamide (c), doxorubicin (a), and 5-fluorouracil (f) as adjuvant treatment of stage II, node+, female breast cancer. Proc Am Soc Clin Oncol 11:51

    Google Scholar 

  13. Cairo MS Mauss D et al. (1990) Prophylactic or simultaneous use of recombinant human granulocyte colony-stimulating factor in the treatment of group B streptococcal sepsis in neonatal rats. Pediatr Res 27:612–616

    Google Scholar 

  14. Cohen AM, Hines DK et al. (1988) In vivo activation of neutrophil function in hamsters by recombinant human granulocyte colony-stimulating factor. Infect Immun 56:2861–2865

    Google Scholar 

  15. Crawford J, Kreisman H et al. (1992) A pharmacodynamic investigation of recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) schedule variation in patients with small cell lung cancer (SCLC) given CAE chemotherapy. Proc Am Soc Oncol 11:298

    Google Scholar 

  16. Crawford J, Ozer H et al. (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164–170

    Google Scholar 

  17. Dale DC, Bonifia MA et al. (1993) A randomized controlled phase-III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 81:2496–2502

    Google Scholar 

  18. Decoster G (1990) Tolerability profile of recombinant metHUG-CSF (Amgen). Ann Oncol 1:80

    Google Scholar 

  19. Delwel R, Salem M et al. (1988) Growth regulation of human acute myeloid leukemia: effects of five recombinant hematopoietic factors in a serum-free culture system. Blood 72:1944–1949

    Google Scholar 

  20. DeVita VTJ, Jaffe ES et al. (1989) Lymphocytic lymphomas. In: DeVita VTJ, Hellman S, Rosenberg SA (eds) Cancer principles and practice of oncology. Lippincott, Philadelphia, pp 1741–1798

    Google Scholar 

  21. Dexter TM, Heyworth CM et al. (1990) The role of growth factors in self-renewal and differentiation of haemopoietic stem cells. Philos Trans R Soc Lond 327:85–98

    Google Scholar 

  22. Duhrsen U, Villeval JL et al. (1988) Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 72:2074–2081

    Google Scholar 

  23. Fukuda M, Kojima S et al. (1992) Autotransplantation of peripheral blood stem cells mobilized by chemotherapy and recombinant human granulocyte colony-stimulating factor in childhood neuroblastoma and non-Hodgkin's lymphoma. Br J Hematol 80:327–331

    Google Scholar 

  24. Fukunaga R, Ishizaka-Ikeda E et al. (1991) Functional domains of the granulocyte colony-stimulating factor receptor. EMBO J 10:2855–2865

    Google Scholar 

  25. Gabrilove JL, Jakubowski A et al. (1988) Phase-I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest 82:1454–1461

    Google Scholar 

  26. Gabrilove JL, Jakubowski A et al. (1988) Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414–1422

    Google Scholar 

  27. Gianni AM, Siena S et al. (1989) Granulocyte-macrophage colony-stimulating factor to harvest circulating haematopoietic stem cells for autotransplantation. Lancet 2:580–585

    Google Scholar 

  28. Gisselbrecht C, Prentice HG et al. (1994) Placebo-controlled phase-III trial of lenograstim in bone-marrow transplantation. Lancet 343:696–700

    Google Scholar 

  29. Greenberg P, Taylor K et al. (1993) Phase-III randomised multicenter trial of G-CSF vs. Observation for myelodysplastic syndrome (MDS). Blood 82 [Suppl]:196a

    Google Scholar 

  30. Griffin JD, Young D et al, (1986) Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia. Blood 67:1448–1453

    Google Scholar 

  31. Groopman JE, Molina J-M et al. (1989) Hematopoietic growth factors: biology and clinical applications. N Engl J Med 321:1449–1459

    Google Scholar 

  32. Haas R, Hohaus H et al. (1992) Autologous blood stem cell transplantation in Hodgkin's disease the impact of rhG-CSF on blood stem cell collection. Bone Marrow Transplant 10:5

    Google Scholar 

  33. Hebert JC, O'Reilly M et al. (1990) Protective effect of recombinant human granulocyte colony-stimulating factor against pneumococcal infection in splenectomized mice. Arch Surg 125:1075–1078

    Google Scholar 

  34. Hellman S, Jaffe ES et al. (1989) Hodgkin's disease. In: DeVita VT, Hellman S, Rosenberg S (eds) Cancer principles and practice of oncology. Lippincott, Philadelphia, pp 1696–1740

    Google Scholar 

  35. Henderson IC, Hayes DF et al. (1988) Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol 6:1501–1515

    Google Scholar 

  36. Hohaus S, Goldschmidt H et al. (1993) Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. Exp Hematol 21:508–514

    Google Scholar 

  37. Hryniuk W, Levine MN (1986) Analysis of dose intensity for adjuvant chemotherapy trials in ovarian cancer. J Clin Oncol 4:1162

    Google Scholar 

  38. Iki S, Yoshinaga K et al. (1993) Cytotoxic drug-induced pneumonia and possible augmentation by G-CSF — clinical attention. Ann Hematol 66:217–218

    Google Scholar 

  39. Inoue C, Murate T et al. (1990) Response of leukemic cells to the sequential combination of GM-CSF and G-CSF. International J Cell Cloning 8:54–62

    Google Scholar 

  40. Kanazawa M, Ishizaka A et al. (1992) Granulocyte colony-stimulating factor does not enhance endotoxin-induced acute lung injury in guinea pigs. Am Rev Resp Dis 145:1030–1035

    Google Scholar 

  41. Katoh M, Shikoshi K et al. (1993) Development of interstitial pneumonitis during treatment with granulocyte colony-stimulating factor. Ann Hematol 67:201–202

    Google Scholar 

  42. Kawakami M, Tsutsumi H et al. (1990) Levels of serum granulocyte colony-stimulating factor in patients with infections. Blood 76:1962–1964

    Google Scholar 

  43. Kawano Y, Takaue Y et al. (1993) Effects of progenitor cell dose and preleukapheresis use of human recombinant granulocyte colony-stimulating factor on the recovery of hematopoiesis after blood stem cell autografting in children. Exp Hematol 21:103–108

    Google Scholar 

  44. Kaye SB, Lewis CR et al. (1992) Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 340:329–333

    Google Scholar 

  45. Koizumi T, Kubo K et al. (1993) Granulocyte colony-stimulating factor does not exacerbate endotoxin-induced lung injury in sheep. Am Rev Resp Dis 148:132–137

    Google Scholar 

  46. Laver J, Moore MAS (1989) Clinical use of recombinant human haematopoietic growth factors. Natl Cancer Inst 81:1370–1382

    Google Scholar 

  47. Lindemann A, Herrmann F et al. (1989) Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. Blood 74:2644–2651

    Google Scholar 

  48. Lord BI, Bronchud MH et al. (1989) The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc Natl Acad Sci USA 86:9499–9503

    Google Scholar 

  49. Maher M, Green J et al. (1993) Randomized, placebo-controlled trial of filgrastim (r-metHuG-CSF) in patients with febrile neutropenia (FN) following chemotherapy (CT). Proc Am Soc Oncol 12:443

    Google Scholar 

  50. Maslack P, Weiss M et al. (1993) Combination of biologic agents with chemotherapy limits toxicity in the treatment of elderly patients with AML. Blood 82S:130a

    Google Scholar 

  51. Matthews JH (1993) Pulmonary toxicity of ABVD chemotherapy and G-CSF in Hodgkin's disease: possible synergy. Lancet 342:988

    Google Scholar 

  52. McGuire WP, Hoskins WJ et al. (1992) A phase-III trial of dose-intense (DI) versus standard-dose (DS) cisplatin (CDDP) and cytoxan (CTX) in advanced ovarian cancer (AOC). Proc Am Soc Clin Oncol 11:226

    Google Scholar 

  53. Mempel K, Pietsch T et al. (1991) Increased serum levels of granulocyte colony-stimulating factor (G-CSF) in patients with severe congenital neutropenia. Blood 77:1919–1922

    Google Scholar 

  54. Meropol NJ, Miller LL et al. (1992) Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Nat Cancer Inst 84:1201–1203

    Google Scholar 

  55. Michon J, Hartmann O et al. (1992) Preliminary analysis of the first open-label randomized phase-III study of recombinant granulocyte colony-stimulating factor as an adjunct to combination induction chemotherapy in pediatric patients with metastatic neuroblastoma. Blood 80 [Supp] 1:248a

    Google Scholar 

  56. Minna JD, Pass H et al. (1989) Cancer of the lung. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer principles and practice of oncology. Lippincott, Philadelphia, pp 591–705

    Google Scholar 

  57. Morstyn G, Campbell L et al. (1988) Clinical studies with granulocyte colony-stimulating factor (G-CSF) in patients receiving cytotoxic chemotherapy. Behring Inst Mitt 83:234–239

    Google Scholar 

  58. Morstyn G, Campbell L et al. (1988) Effect of granulocyte colony-stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1:667–672

    Google Scholar 

  59. Nagata S, Tsuchiga M et al. (1986) Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature 319:415–418

    Google Scholar 

  60. Negrin RS, Haeuber DH et al. (1989) Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I–II trial. Ann Intern Med 110:976–984

    Google Scholar 

  61. Negrin RS, Haeuber DH et al. (1990) Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 76:36–43

    Google Scholar 

  62. Nicola NA (1987) Why do hemopoietic growth factor receptors interact with each other. Immunol Today 8:134–140

    Google Scholar 

  63. Nicola NA (1989) Hemopoietic cell growth factors and their receptors. Annu Rev Biochem 58:45–77

    Google Scholar 

  64. Ohno R, Hiraoka A et al. (1993) No increase of leukemia relapse in newly diagnosed patients with acute myeloid leukemia who received granulocyte colony-stimulating factor for life-threatening infection during remission induction and consolidation therapy. Blood 81:561–562

    Google Scholar 

  65. Ohno R, Tomonaga M et al. (1990) Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 323:871–877

    Google Scholar 

  66. Ottmann OG, Ganser A et al. (1993) Simultaneous administration of granulocyte colony-stimulating factor (filgrastim) and induction chemotherapy in acute lymphoblastic leukemia (ALL). Ann Hematol 67:161–167

    Google Scholar 

  67. Ottmann OG, Hoelzer D et al. (1993) Concomitant R-metHuG-CSF (filgrastim) and intensive chemoradiotherapy as induction treatment in adult ALL: a randomised multicenter phase-III trial. Blood 82S:193a

    Google Scholar 

  68. Peters WP, Kurtzberg J et al. (1989) Comparative effects of rHuG-CSF and rHuGM-CSF on hematopoietic reconstitution and granulocyte function following high-dose chemotherapy and autologous bone marrow transplantation (ABMT). Proc Am Soc Clin Oncol 8:181

    Google Scholar 

  69. Petros WP, Peters WP (1993) Hematopoietic colony-stimulating factors and dose intensity. Semin Oncol 20:94–99

    Google Scholar 

  70. Pettengell R, Gurney H et al. (1992) Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 80:1430–1436

    Google Scholar 

  71. Pettengell R, Morgenstern GR et al. (1993) Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. Blood 82:3770–3777

    Google Scholar 

  72. Philip T, Armitage JO et al. (1987) High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 316:1493–1498

    Google Scholar 

  73. Platzer E, Welte K et al. (1985) Biological activities of a human pluripotent hematopoietic colony-stimulating factor on normal and leukemic cells. J Exp Med 162:1788–1801

    Google Scholar 

  74. Roilides E, Walsh TJ et al. (1991) Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis 163:579–583

    Google Scholar 

  75. Samson MK, Rivkin SE et al. (1984) Dose-response and dose-survival advantage for high- versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. Cancer 53:1029–1035

    Google Scholar 

  76. Sartorelli KH, Silver GM et al. (1991) The effect of granulocyte colony-stimulating factor (G-CSF) upon burn-induced defective neutrophil chemotaxis. J Trauma 31:523–529

    Google Scholar 

  77. Sato N, Shimizu H (1993) Granulocyte-colony stimulating factor improves an impaired bactericidal function in neutrophils from STZ-induced diabetic rats. Diabetes 42:470–473

    Google Scholar 

  78. Scherrer R, Geissler K et al. (1993) Granulocyte colony-stimulating factor (G-CSF) as an adjunct to induction chemotherapy of adult acute lymphoblastic leukemia (ALL). Ann Hematol 66:283–289

    Google Scholar 

  79. Schmitz N, Dreger P et al. (1993) A randomized, controlled, multicentre study of granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Blood 82.S:146a

    Google Scholar 

  80. Sheridan WP, Begley CG et al. (1992) Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 339:640–644

    Google Scholar 

  81. Sheridan WP, Morstyn G et al. (1989) Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 2:891–895

    Google Scholar 

  82. Shishido K, Nukura K et al. (1991) The effects and pharma-cokinetics of rhG-CSF on the treatment of neutropenia in patients with renal failure. Nippon Jinzo Gakkai Shi 33:973–981

    Google Scholar 

  83. Shpall EJ, Jones RB et al. (1993) Transplantation of enriched autologous CD34+ hematopoietic progenitor cells into breast cancer patients following high-dose chemotherapy. Am Soc Clin Oncol 12:105

    Google Scholar 

  84. Skipper HE (1967) Criteria associated with destruction of leukemia and solid tumor cells in animals. Cancer Res 27:2636–2645

    Google Scholar 

  85. Souza LM, Boone TC et al. (1986) Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 232:61–65

    Google Scholar 

  86. Stahel RA, Lorenz MJ et al. (1994) A randomized study of recombinant human granulocyte colony-stimulating factor (filgrastim) after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol, in press

  87. Stute N, Santana VM et al. (1992) Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood 79:2849–2854

    Google Scholar 

  88. Tanaka H, Tokiwa T (1990) Influence of renal and hepatic failure on the pharmacokinetics of recombinant human granulocyte colony-stimulating factor (KRN8601) in the rat. Cancer Res 50:6615–6619

    Google Scholar 

  89. Taylor KM, Jagannath S et al. (1989) Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol 7:1791–1799

    Google Scholar 

  90. Teshima H, Ishikawa J et al. (1989) Clinical effects of recombinant human granulocyte colony-stimulating factor in leukemia patients: a phase-I/II study. Exp Hematol 17:853–858

    Google Scholar 

  91. Trillet-Lenoir V, Green J et al. (1993) Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319–324

    Google Scholar 

  92. Vadhan-Raj S, Keating M et al. (1987) Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 317:1545–1549

    Google Scholar 

  93. Valerius T, Repp R et al. (1993) Involvement of the high-affinity receptor for IgG (FcγRI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. Blood 82:931–939

    Google Scholar 

  94. van Rijswijk R, Haanen C et al. (1989) Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease. J Clin Oncol 7:1776–1782

    Google Scholar 

  95. Vellenga E, Ostapovicz D et al. (1987) Effects of recombinant IL-3, GM-CSF and G-CSF on proliferation of leukemic clonogenic cells in short-term and long-term cultures. Leukemia 1:584–589

    Google Scholar 

  96. Watari K, Asano S et al. (1989) Serum granulocyte colony-stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay. Blood 73:117–122

    Google Scholar 

  97. Welte K, Mempel K et al. (1993) A randomised phase-III study of recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in childhood high-risk acute lymphoblastic leukemia. Blood 82S:194a

    Google Scholar 

  98. Welte K, Platzer E et al. (1985) Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci USA 82:1526–1530

    Google Scholar 

  99. Welte K, Zeidler C et al. (1990) Differential effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia. Blood 75:1056–1063

    Google Scholar 

  100. Yasuda H, Ajiki Y et al. (1990) Therapeutic efficacy of granulocyte colony-stimulating factor alone or in combination with antibiotics againsPseudomonas aeruginosa infections in mice. Infect Immun 58:2502–2509

    Google Scholar 

  101. Yoshida Y, Hirashima K et al. (1991) A phase-II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes. Br J Hematol 78:378–384

    Google Scholar 

  102. Zeidler C, Reiter A et al. (1993) Langzeitbehandlung mit rekombinanten humanen Granulozyten-Kolonien stimulierendem Faktor bei Patienten mit schwerer kongenitaler Neutropenie. Klin Padiatr 205:264–271

    Google Scholar 

  103. Zeidler C, Reiter A et al. (1994) Long-term effects of r-metHuG-CSF treatment in patients with severe congenital neutropenia. Rev Invest Clin [Suppl]:251

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. AMGEN GmbH, Munich, Riesstrasse 25, D-80992, Munich, Germany

    G. Schwab & T. Hecht

Authors
  1. G. Schwab
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Hecht
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schwab, G., Hecht, T. Recombinant methionyl granulocyte colony-stimulating factor (filgrastim): A new dimension in immunotherapy. Ann Hematol 69, 1–9 (1994). https://doi.org/10.1007/BF01757341

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01757341

Keywords

Search

Navigation